Jared Holz
Jared Holz is a financial analyst at Mizuho Securities, known for his expertise in the pharmaceutical sector. Recently, he commented on Pfizer's struggles to excite investors due to a lack of promising new products in its pipeline and the company's ongoing efforts to manage costs amidst declining sales, particularly in the wake of diminishing demand for COVID-19 related treatments.
Not in the pool (under ¢1).
Recent news mentions
Jared Holz, an analyst with Mizuho, said in a note to clients that the actual comment from the President is direct but its impact may be somewhere between nebulous and negligible.
Pharmaceutical tariffs: A 100% tariff on some imported drugs is coming October 1, Trump says
United States· 2025-09-26
Mizuho Securities healthcare specialist Jared Holz commented on the potential impact of the tariffs.
Trump announces new tariffs on pharmaceuticals from October – The Irish Times
Ireland· 2025-09-26
Mizuho analyst Jared Holz stated that investors are just not excited about the current Pfizer business or the pipeline.
Pfizer’s Irish staff worry about more job losses as drugmaker announces another €1.5bn in cuts – The Irish TimesIreland· 2025-04-29
